Altimmune, Inc. (ALT) Financial Analysis & Valuation | Quarter Chart
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the ... more
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for ob... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $635.93M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Jerome Benedict Durso |
| IPO Date | 2017-05-26 | CAGR | -12.45% |
| Employees | 57 | Website | altimmune.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ALT chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $576.59M | P/E | -4.19 | Forward P/E | -4.89 | PEG | — |
| P/S | 253625.46 | P/B | 15.86 | P/CF | -98 | P/FCF | -102.71 |
| Sales | $31,000 | Sales 1Y | 55% | Sales 3Y | -138.27% | Sales 5Y | -99.5% |
| EPS | $-0.78 | EPS 1Y | -33.9% | EPS 3Y | -50.32% | EPS 5Y | -56.42% |
| Sales QoQ | — | EPS QoQ | -33.33% | Sales QoQ Avg | — | EPS QoQ Avg | -15.08% |
| Gross Margin | -48232.26% | Operating Margin | -323306.45% | Profit Margin | -296000% | ROCE | -19.47% |
| ROA | -17% | ROE | -31% | Altman Z Score | 5.63 | Piotroski Score | 3 |
| Current Ratio | 26.78 | Quick Ratio | 26.78 | Cash Ratio | 5.04 | Op. CF Ratio | -1.94 |
| Debt/Equity | — | Debt/Assets | 0.07 | Lt Debt/Equity | 0.08 | Lt Debt/Cap. | — |
| Intrst Cov. | -28.34 | Inventory Turnover | — | Asset Turnover | 0 | Receivables Turnover | 0.01 |
| Enterprise Value | $576.59M | P/E Ratio | -4.19 |
| Forward P/E | -4.89 | PEG Ratio | — |
| P/S Ratio | 253625.46 | P/B Ratio | 15.86 |
| P/CF Ratio | -98 | P/FCF Ratio | -102.71 |
| EPS | $-0.78 | EPS Growth 1Y | -33.9% |
| EPS Growth 3Y | -50.32% | EPS Growth 5Y | -56.42% |
| Revenue Growth 1Y | 55% | Gross Margin | -48232.26% |
| Operating Margin | -323306.45% | Profit Margin | -296000% |
| ROE | -31% | ROA | -17% |
| ROCE | -19.47% | Current Ratio | 26.78 |
| Quick Ratio | 26.78 | Cash Ratio | 5.04 |
| Debt/Equity | — | Interest Coverage | -28.34 |
| Altman Z Score | 5.63 | Piotroski Score | 3 |
Altimmune, Inc. (ALT) valuation & financials
Altimmune, Inc. (ALT) has a market capitalization of $635.93M and trades at a price-to-earnings ratio of -4.2. It operates in the Healthcare sector (Biotechnology).
Altimmune, Inc.'s revenue grew +55.0% over the last year.
Altimmune, Inc.'s next earnings report is scheduled for November 5, 2026 before market open (provider scheduled date); analysts estimate EPS of $-0.14. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)